Mylan announces tentative approval for Rabeprazole sodium delayed-release tablets

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Jan 23 2006

Mylan Laboratories Inc. has announced that the U.S. Food and Drug Administration has granted tentative approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application for Rabeprazole Sodium Delayed-release Tablets, 20 mg.

Rabeprazole Sodium Delayed-release Tablets are the generic version of Eisai Medical Research Inc.'s Aciphex(R) Tablets, which had annual U.S. sales of approximately $1.3 billion as of June 2005.

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories, Inc. that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.

Source:

http://www.mylan.com/

Posted in: Pharmaceutical News

Tags: , , , , ,

Comments (0)

Suggested Reading

Study reveals daily food environment exposure shapes fast food habits
Maternal influences on food allergy prevention: A closer look at diet and environment
Korean fermented food Doenjang shows promise in alleviating menopausal symptoms
How can food influence the severity of menopausal hot flashes?
Food additive emulsifiers linked to increased risk of type 2 diabetes
Feeling lonely? It may affect how your brain reacts to food, new research suggests
Study links ultra-processed food consumption with higher cardiovascular risk
Ultra-processed foods raise chronic kidney disease risk, study shows

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Food allergies' broad impact on quality of life demands greater awareness